Protalix BioTherapeutics Inc PLX shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint.
Fabry disease is an inherited disease resulting in progressive accumulation of abnormal deposits of a fatty substance in blood vessel walls throughout a person's body.
"Based on results from our clinical program, we believe that PRX–102, as a PEGylated enzyme replacement therapy with potentially two different dosing regimens, may be a valuable new treatment option for individuals suffering from Fabry disease," said Dror Bashan, president and CEO of Protalix BioTherapeutics.
Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ProCellEx plant cell–based protein expression system.
See Also: Why Gores Guggenheim Shares Are Rising Today
PLX 52-Week Range: $0.70 - $6.64
The stock was up 64.3% at $1.72 at time of publication, according to data from Benzinga Pro.
Photo: Belova59 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
